Company intelligence / Profile preview

Brain Neurotherapy Bio

Columbus, Ohio, United Statesaskbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company's lead program, AB-1005 (AAV2-GDNF), met its primary safety endpoint in a Phase 1b trial for Parkinson's disease. The company is also conducting a Phase 1/2 study for Multiple System Atrophy. As of January 2024, AskBio plans to commence a Phase II trial for Parkinson's disease with screening anticipated to begin in the first half of 2024[6].

Therapeutic areas: Neurology
Modalities: Gene therapyAAV (adeno-associated virus) gene therapy
Industry: Pharma

Drug pipeline

1 asset

AAV2-GDNF

Phase 1

Indications: Parkinson's disease, Multiple system atrophy

Partnerships

AskBio (merged with)

Beyond the preview

Go deeper on Brain Neurotherapy Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brain Neurotherapy Bio.

Explore the full profile